Jade Biosciences Q2 Results: JADE101 Positive, Cash $461M
Jade Biosciences reported positive Phase 1 data for JADE101 and announced the start of a Phase 2 trial, bolstered by robust cash reserves expected to fund operations into late 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day